BioCentury | Apr 4, 2020
Finance

Investors are seeking only one thing: a sign the pandemic tide is shifting

The usual clinical and commercial catalysts are taking a back seat in the second quarter as buysiders are almost solely focused on COVID-19 milestones that will stabilize the market. On the other hand, the virtual...
BioCentury | Apr 4, 2020
Product Development

COVID-19 roundup: FDA’s expanded access program for convalescent plasma; plus more funding from BARDA, tests from Eurofins, BD-BioGx, and more

BARDA’s latest push into plasma-based COVID-19 therapies includes an expanded access program for convalescent plasma and funding for Emergent’s hyperimmune program. To combat the pandemic, a pair of companies began rolling out tests, while GSK...
BioCentury | Apr 3, 2020
Finance

Oncology company Zentalis posts double-digit gain after pricing upsized IPO

For the handful of biotechs waiting in the IPO queue, Zentalis’ upsized offering and early aftermarket performance offer encouraging signs that the public markets remain receptive to new biopharma listings, even amid weeks of uncertainty...
BioCentury | Apr 3, 2020
Product Development

April 2 Quick Takes: Horizon takes out Curzion; plus Rgenta, Merck, Novartis-Aurobindo, Kite, Teneobio and Seattle Genetics

Horizon gains sclerosis candidate via Curzion deal  Horizon Therapeutics plc (NASDAQ:HZNP) acquired privately held Curzion Pharmaceuticals Inc., giving it LPAR1 antagonist HZN-825 (CZN001). Curzion’s shareholders received $45 million up front and are eligible for milestones...
BioCentury | Apr 3, 2020
Product Development

COVID-19 roundup: Amgen taps Adaptive as its antibody therapeutic partner; plus Alnylam-Vir’s siRNA targets, Ansun’s data and more

Amgen entered the race to develop an antibody-based COVID-19 therapy Thursday, partnering with Adaptive Biotechnologies to screen for neutralizing mAbs. The day also saw Alnylam and Vir name the first targets from their siRNA partnership...
BioCentury | Apr 2, 2020
Politics, Policy & Law

VC-backed biotechs may be excluded from coronavirus loan program

Venture-backed companies may be shut out of an emergency forgivable loan program for small businesses created by the Coronavirus Aid, Relief, and Economic Security (CARES) Act unless the Trump administration takes urgent action to modify...
BioCentury | Apr 2, 2020
Product Development

April 1 Quick Takes: Gedeon gets Europe rights to Myovant’s uterine fibroid therapy following MAA submission; plus Orion-Bayer, BMS-bluebird, Mesoblast and more

Myovant licenses relugolix rights to Gideon for $40M  Myovant Sciences GmbH (NYSE:MYOV) licensed rights of relugolix combination tablets to Gedeon Richter plc (Budapest:RICHTER) in Europe, Russia, Latin America, Australia and New Zealand. Myovant, which retains...
BioCentury | Apr 1, 2020
Emerging Company Profile

Aspen plans to drive iPS cell therapy into Parkinson’s patients with $70M A round

Aspen plans to bring its autologous iPS cell-based therapy into Parkinson’s disease patients while exploring the stem cell platform in new indications with a $70 million series A round led by OrbiMed Advisors. Existing investors...
BioCentury | Mar 31, 2020
Product Development

COVID-19 roundup: Qiagen, BD-BioMedomics, Rendu, Vaxart, Cobra, GigaGen, Houston Methodist, Anaqua-WideTrial

FDA’s emergency use authorization for a Qiagen test Tuesday comes amid a flurry of advancements in therapeutic, vaccine and diagnostic COVID-19 programs, including GigaGen’s unveiling of a polyclonal antibody program derived from convalescent COVID-19 patients....
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

Qiagen N.V. (NYSE:QGEN; Xetra:QIA) said Thierry Bernard will become the permanent CEO after serving on an interim basis since October. Bernard, who joined Qiagen in 2015 as SVP of the molecular diagnostics business area, takes...
Items per page:
1 - 10 of 14624